AACR 2024
Apr 05, 2024
Advancements in Targeting KRASG12D: Preclinical Insights and Therapeutic Potential
KRAS mutations represent the most commonly encountered driver oncogene, implicated in approximately 25% of all human cancers, with KRASG12D emerging as a predominant isoform, particularly prevalent in pancreatic, colorectal, and non-small cell lung cancers. Despite its frequency, targeting KRASG12D poses distinct c...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
